Jade Biosciences announced the acceleration of its JADE101 clinical program for treating immunoglobulin A nephropathy (IgAN), with the Phase 3 EVERGREEN trial now expected to start in Q4 2026. JADE101 is an investigational antibody targeting APRIL, designed to reduce IgA levels and potentially slow kidney disease progression. Interim data from the ongoing Phase 2 JUNIPER trial is anticipated in Q2 2027, supporting further development. These advancements highlight Jade's commitment to developing a potentially best-in-class therapy for IgAN, a chronic autoimmune kidney disease affecting many young adults.
Jade Biosciences' JADE101 development program progress is noted here alongside Pluang's health sector market data as of Oct 21, 2026 18:11 WIB. Of 150 priced health-sector US stocks tradable on Pluang, 71 rose and 67 fell today. Notable movers include ROIV at USD 36.91 with a 1-day change of +5.70% and a typical hold time of 9 days, Danaher Corporation (DHR) at USD 212.10 down 5.32% with 79% sell order activity and a typical hold time of 69 days, and Twist Bioscience Corp (TWST) at USD 137.09 down 3.93% but with 100% buy order activity and a typical hold time of 27 days.
The Human Feedback Foundation, supported by RBC, has launched the Agentic AI Design Exchange, a national program aimed at helping Canadian nonprofits design, build, and deploy AI agents responsibly. Funded through RBC's Stronger Nonprofits Program, t...
Satellos Bioscience Inc., a clinical-stage company focused on treatments for degenerative muscle diseases, announced its management will participate in two investor conferences in November: the Guggenheim Healthcare Innovation Conference on Nov 9 in ...
YYForce Inc. has purchased 20 wearable data collection systems to gather real task data from hotel room service at Novotel Singapore. This project aims to record and analyze experienced staff performing tasks like bed-making, towel folding, and clean...
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, at a compound annual growth rate of 20.2%. This growth is driven by increasing demand for chronic disease managem...
The global private credit and alternative lending market, valued at $2.31 trillion in 2026, is expected to grow at a 7.8% CAGR to reach $3.36 trillion by 2031. Recent liquidity pressures in 2025, triggered by bankruptcies and AI sector concerns, caus...
